Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone inhibits CYP17A1, blocks androgen synthesis, and prolongs survival in prostate cancer.
D4-Abiraterone is an inhibitor of CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid 5a-reductase (SRD5A), the main metabolite of abiraterone. D4-Abiraterone is also an antagonist of androgen receptor.